Pre-start-up package program awarded (KISED)
MetaImmuneTech Inc. established (Capital 92.5 million KRW)
Selected as Best Company in the pre-start-up package program
Acquisition of patents related to obesity treatment from Korea University
First stage Start-up package program awarded (KISED)
Investment from Korea University Holdings (Seed, 100 million KRW)
Acquisition of patents related to LSIT-based NK cell activity assay from KU
TIPS R&D grant awarded (MSS, 500 million KRW)
Clinical research of Cellytics NK started in collaboration with KUH Anam (Normal vs Cancer)
Commercialization Support Program granted (MSS)
Investment from SRI OB Private fund (70 million KRW)
Establishment of Corporate Research Institute (KU Sejong campus)
Science Belt R&D Grant awarded (MSIT, 1 billion KRW)
ITRC program awarded (MSIT)
CellyticsTM NK prototype completed (System + Reagent kit)
Clinical research of Cellytics NK in Hematologic cancer started (KUH Ansan)
Clinical research of Cellytics NK in Liver disease started (KUH Guro)
Clinical research in NSCLC patient monitoring with NK cell therpay (Vaxcell Bio, CNUHH)
Cellytics NK – CES 2024 Innovation Award Honoree (Digital Health)